The specificity of VTP-50469 against KMT2A-rearranged leukemia was further reinforced by its inability to significantly delay the progression of a BCR::ABL1 fusion-positive ALL PDX (Krivtsov et al., 2019). The gene discussed is ABL1; the disease is leukemia.